Compare Bristol-Myers Squibb Co (BMY) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Tyson Foods, Inc. — how do they compare? Bristol-Myers Squibb Co trades at $57.13 (market cap $121.18B), while Tyson Foods, Inc. trades at $57.45 (market cap $20.40B). The key difference: Bristol-Myers Squibb Co is far larger — about 5.9× Tyson Foods, Inc.'s market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.25%). Which is the better fit depends on your goals.
| BMY | TSN | |
|---|---|---|
Market Cap | $121.18B | $20.40B |
Sector | Health | Consumer Staples |
52-Week High | $62.37 | $68.75 |
52-Week Low | $42.60 | $50.72 |
Enterprise Value | $157.12B | $27.98B |
Dividend Yield | 4.25% | 3.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Tyson Foods (TSN) trades at $57.92, up 0.16% on the day, with a bearish technical signal but mixed earnings performance including a Q1 2026 beat. The company shows modest revenue growth to $54.44 billion in 2025, though net margins are thin at 0.81%. Recent news highlights innovation in prepared foods and new leadership appointments, while analyst consensus leans bullish with a $68.80 price target.
The stock presents a value opportunity with low P/S and P/B ratios, but faces risks from volatile earnings, high debt, and competitive pressures. Upside depends on execution in value-added segments and cost management, with the current price offering a 19% discount to the consensus target.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
